{
    "clinical_study": {
        "@rank": "60228", 
        "arm_group": [
            {
                "arm_group_label": "OxyNorm Capsules", 
                "arm_group_type": "Experimental", 
                "description": "To determine the efficacy and safety of OxyNorm Capsules."
            }, 
            {
                "arm_group_label": "Morphine tablet", 
                "arm_group_type": "Active Comparator", 
                "description": "To determine the efficacy and safety of Morphine tablet."
            }
        ], 
        "brief_summary": {
            "textblock": "The efficacy and safety of oxycodone capsules compared with morphine tablets in hospitalized\n      patients with moderate to severe pain following surgery."
        }, 
        "brief_title": "OxyNorm Capsules in Post-Operative Pain Study", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": "Postoperative Pain", 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "detailed_description": {
            "textblock": "To evaluate the efficacy and safety of oxycodone immediate-release capsules compared with\n      morphine immediate-release tablets in hospitalized patients with moderate to severe pain\n      following surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients of either sex aged 18 to 80 years inclusive.\n\n          2. Patients who have given written informed consent to participate in the study.\n\n          3. Able and willing to communicate with the investigator and his/her staff.\n\n          4. Free of anesthesia as assessed through question and answer interaction with nurse at\n             which time oral medication is indicated.\n\n          5. Reporting \"moderate\" or \"severe\" pain (VAS \u2265 4) related to surgery and requesting\n             analgesics for pain relief.\n\n        Exclusion Criteria:\n\n          1. Patients have developed tolerance to or dependence on narcotic analgesics and/or\n             alcohol.\n\n          2. Patients with ASA \u2265 3 .\n\n          3. Have any concomitant medical condition that would be adversely affected by analgesics\n             or confound the quantification of analgesia, or could affect the absorption,\n             metabolism or excretion of the study drugs in any clinically significant fashion.\n\n          4. Have known hypersensitivity to any of the study medications or related agents.\n\n          5. Have taken analgesic medications within three hours (wash-out) prior to dosing.\n\n          6. Have developed complications from the surgical procedure that would confound the\n             study.\n\n          7. Have a history of severe iatrogenic adverse experiences.\n\n          8. Mothers nursing their infant during the 24 hours following study drug administration,\n             or pregnant women.\n\n          9. Patient with non-peros (NPO) as stated in patient's chart or physician's order.\n\n         10. Surgery in patients with epidural anesthesia\n\n         11. Patients with Severe impairment of liver at preoperative stage (ALT, AST \u2265 1.5 times\n             upper limit) and abnormal renal function.\n\n         12. Patients with medical history of recovering from abnormal surgery anesthesia.\n\n         13. Patients with medical history of hypertension (Systolic blood pressure \u2265 180Hg,\n             Diastolic blood pressure 110Hg).\n\n         14. Patients with shock.\n\n         15. Patients with COPD.\n\n         16. According to investigator to determine, patients are in addition the inclusion\n             criteria and exclusion criteria for any other reason than not suitable in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675635", 
            "org_study_id": "OXYC11-CN-304"
        }, 
        "intervention": [
            {
                "arm_group_label": "OxyNorm Capsules", 
                "description": "dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours", 
                "intervention_name": "OxyNorm Capsules", 
                "intervention_type": "Drug", 
                "other_name": "OxyNorm"
            }, 
            {
                "arm_group_label": "Morphine tablet", 
                "description": "dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.", 
                "intervention_name": "Morphine tablet", 
                "intervention_type": "Other", 
                "other_name": "Morphine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Morphine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 8, 2012", 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety, of Oxycodone Immediate-release Capsules Versus Morphine Immediate-release Tablets in Hospitalized Patients With Moderate to Severe Pain Following Surgery.", 
        "overall_official": {
            "affiliation": "Peking University 1st Hospital", 
            "last_name": "XinMin Wu, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To measure resting VAS at 6h(\u00b120min) after administration of first dose, assessing the intensity of pain, and to comduct inter-group comparison", 
            "measure": "Resting VAS at 6h after administration of first dose", 
            "safety_issue": "No", 
            "time_frame": "at 6h after administration of first dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675635"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To measure coughing VAS at 6h (\u00b120min) after administration of first dose, assessing the intensity of pain, and to comduct inter-group comparison", 
                "measure": "Coughing VAS at 6h after administration of first dose", 
                "safety_issue": "No", 
                "time_frame": "at 6h after administration of first dose"
            }, 
            {
                "description": "To calculate the amount of rescue analgesics used during the 24-hour observation period and to comduct inter-group comparison", 
                "measure": "The amount of rescue analgesics used during the 24-hour observation period", 
                "safety_issue": "No", 
                "time_frame": "during 24 hours period after the first dose."
            }, 
            {
                "description": "To measure the resting and coughing VAS as 0.5h (\u00b15min), 2h (\u00b110min) and 24h (\u00b120min) after administration of first dose, assessing the intensity of pain and to comduct inter-group comparison", 
                "measure": "Resting and coughing VAS at 0.5h, 2h and 24h after administration of first dose", 
                "safety_issue": "No", 
                "time_frame": "every 6 hours with the 24 hours period after first dose"
            }, 
            {
                "description": "To assess Sleeping quality assessment during 24 hours after administration of first dose and to comduct inter-group comparison", 
                "measure": "Sleeping quality assessment", 
                "safety_issue": "No", 
                "time_frame": "24 hours after administration of first dose"
            }, 
            {
                "description": "To assess the Satisfaction with pain control during 24 hours after administration of first dose and to comduct inter-group comparison", 
                "measure": "Satisfaction with pain control", 
                "safety_issue": "No", 
                "time_frame": "24 hours after administration of first dose"
            }, 
            {
                "description": "To calculate the total amount of study drugs used during the 24 hours and to comduct inter-group comparison", 
                "measure": "comparison of the total amount of study drugs used during the 24 hours", 
                "safety_issue": "No", 
                "time_frame": "24 hours after administration of first dose"
            }, 
            {
                "description": "To calculate the number and rate of each AE and abnormal lab results occuring in the study, and to conduct inter-group comparation.", 
                "measure": "the number and rate of AE and abnormal lab results", 
                "safety_issue": "Yes", 
                "time_frame": "24-48 hours after administration of first dose"
            }
        ], 
        "source": "Mundipharma Pte Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma Pte Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }
}